paclitaxel,olaparib,bevacizumab,carboplatin,durvalumab
roche,merck,astrazeneca
['imfinzi', 'lynparza', 'duo-o', 'bevacizumab', 'astrazeneca']
an interim analysis of the phase iii duo-o trial, presented by at the 2023, revealed that the combination of lynparza, imfinzi, chemotherapy, &amp; bevacizumab reduced the risk of disease progression or death by 37%. read more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry